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Diffuse large B-cell lymphoma (DLBCL) is the most common type
of aggressive lymphoma. The disease is heterogeneous with
respect to the clinical course and molecular ﬁndings, making the
management of these patients challenging. Deepened under-
standing of DLBCL pathogenesis has opened novel possibilities for
early patient prognostication, but a further improved stratiﬁcation
will be essential to allow for individualized, risk-adapted therapy.
So far, few studies have addressed the plasma proteome in DLBCL.
In a recent pilot study we showed that plasma immunoproﬁling,
using recombinant antibody microarrays, could be used to
decipher DLBCL heterogeneity on the protein level, indicating
potential novel patient subgroups that might be linked to
survival.1 Here, we have expanded these immunoproﬁling efforts
by examining the immunoproﬁles of DLBCL patients, using
longitudinal plasma samples collected at the time of diagnosis
and during the treatment. Our aim was to search for prognostic
and potentially predictive protein proﬁles in plasma samples from
DLBCL patients.
The study population consisted of 126 patients with high-risk de
novo DLBCL or follicular lymphoma grade III, included in a
prospective phase II clinical trial of the Nordic Lymphoma Group
during 2004–2008.2 Treatment consisted of six cycles of R-CHOEP-14
followed by systemic central nervous system prophylaxis with one
cycle high-dose cytarabine and one cycle high-dose methotrexate.
In the present study, patients were selected based on available
plasma samples taken at diagnosis as a baseline sample (BL,
n= 116), after cycle 3 (Cy3, n= 61) and/or after the ﬁnal cycle 8
(Cy8, n= 58). Age- and gender-matched healthy controls (n= 40)
were included (Supplementary Table 1).
In recent years, several proteomic methods have been
developed, revealing novel insights into the complex proteome.
Recombinant antibody microarray is a high-throughput proteomic
technique with the ability to detect multiplexed panels of both
high- and low-abundant proteins in different bioﬂuids, providing
protein expression proﬁles that reﬂect the composition of the
proteome.3 A summary of the method and data analysis used in
the present study is given in Supplementary Method,
Supplementary Table 2 and Supplementary Figure 1. So far, the
use of recombinant antibody microarrays has deﬁned disease-
speciﬁc signatures for several solid tumors and inﬂammatory
conditions, by targeting mainly immunoregulatory proteins
thought to reﬂect alterations in the host immune response.4,5 In
addition, a recent pilot study using plasma samples from DLBCL
patients revealed a protein immunoproﬁle of 23 plasma proteins
that could be used to differentiate the patients into two
subgroups with signiﬁcantly different overall survival (OS).1 Here,
our approach was to expand the immunoproﬁling of DLBCL
patients, but in addition also target plasma proteins that are
connected to proliferation and survival of the tumor cells.
The results showed that plasma protein proﬁles could
distinguish newly diagnosed DLBCL patients from healthy
controls. The number of signiﬁcantly deregulated proteins in
baseline samples taken at diagnosis vs samples from healthy
controls was 58 (Supplementary Figure 2). The top 15 most
signiﬁcantly deregulated proteins were mainly upregulated in the
plasma samples from patients, including interleukin (IL)-13,
MAPK2 and tyrosine-protein kinase BTK (BTK). Although it can
be expected that several immunoregulatory proteins have a
different expression in these two groups, it is interesting to look
into some of the differently expressed proteins more closely, such
as the B-cell-stimulating T-helper 2 cytokine IL-13, which was
upregulated in DLBCL patients compared with controls. High
levels of IL-13 were also reported in a recent study on DLBCL
patients, compared with healthy controls.6 Moreover, BTK was
upregulated in the plasma from DLBCL patients. Due to the
prominent role in B-cell receptor signaling, and the promising
clinical results obtained with BTK inhibitors,7 further exploration of
the clinical relevance of BTK levels in the plasma of DLBCL patients
is warranted.
The protein proﬁles indicated massive changes in the plasma
proteome protein during treatment. In particular, large changes in
the plasma proteome were observed upon start of treatment; the
number of signiﬁcantly deregulated proteins being 48 at BL vs
Cy3, compared with only 1 when comparing Cy3 with Cy8, and 0
at BL vs Cy8 (Supplementary Figure 3). In the case of BL vs Cy3, the
top 15 deregulated proteins were all upregulated at Cy3, and
included both T-helper 1 and 2 cytokines, and the monocyte
chemotactic protein-1 (MCP-1). MCP-1 has been reported to be
overexpressed on mRNA and protein levels in aggressive
lymphomas.8 Considering the given treatment with chemother-
apy, corticosteroids, rituximab and granulocyte colony-stimulating
factor, it is difﬁcult to draw any ﬁrm conclusions from the changes
in the plasma proteome seen during treatment. However, the
dynamics are interesting and encourage future studies in the
quest of clinically useful information from protein proﬁles in the
plasma.
Further, we investigated whether protein proﬁles at the time of
diagnosis could classify the patients according to selected clinical
variables. The results indicated that biologically relevant and
differently expressed proteins were observed when comparing
patients with different aaIPI or different failure-free survival (FFS)
(Supplementary Figure 4). For example, cyclin-dependent kinase 2
(CDK-2) and BTK were observed to be upregulated in patients with
higher aaIPI and in patients with shorter FFS. CDK-2 is a crucial
component of cell cycle control, reported to be elevated in several
B-cell malignancies.9 CDK inhibitors represent a promising class of
drugs under development for treatment of a range of tumors,
including DLBCL.10
In order to correlate the total change in expression of each
protein over the three time points (BL, Cy3 and Cy8) to selected
clinical variables, a response feature analysis was performed.
When comparing the patients who developed progression during
treatment with those who did not, six signiﬁcantly deregulated
proteins were identiﬁed, among them IL-6 (Supplementary
Figure 5). High levels of IL-6 in plasma have previously been
correlated to unfavorable prognosis for DLBCL patients.11 Our
ﬁndings indicate that changes in the plasma proteome might be a
helpful tool for early evaluation of treatment response, allowing
rapid changes in the treatment of patients not responding to ﬁrst-
line treatment.
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On the basis of plasma samples taken at diagnosis, and the
protein signature of 23 plasma proteins with prognostic impact
found in a previous pilot study from our group,1 patients in the
present study could be divided into two distinct subgroups,
denoted DLBCLa and DLBCLb, by unsupervised hierarchical
clustering. The proteins in the proﬁle included immunoregulatory
proteins such as T-helper cytokines, chemotactic proteins and
complement factors. Survival analysis of the generated subgroups
showed a tendency toward different survival in the two groups
(Figure 1), supporting the ﬁndings of the pilot study regarding the
prognostic impact of the protein signature and suggesting that
plasma protein proﬁles of newly diagnosed DLBCL patients may
contain valuable prognostic information. The 23 proteins included
in the present protein proﬁle were mainly upregulated in the
subgroup of patients showing a trend toward worse prognosis
and included MCP-1, IL-6, IL-10 and tumor necrosis factor-α (TNF-α)
(Figure 1). In addition, IL-10 and TNF-α were found to be
signiﬁcantly upregulated in patients with short OS, deﬁned as
OSo12 months compared with OS412, 24, 36, 48 or 60 months.
To investigate the prognostic power of these two biomarkers, they
were compared with aaIPI in a Cox survival model. Adding IL-10 or
TNF-α to the aaIPI improved the model, although adding both
simultaneously did so to a lesser extent, indicating that the two
proteins provided collinear information (Table 1). IL-10 is an
immunosuppressive, but also B-cell stimulating, cytokine.12 TNF-α
is an immunostimulatory cytokine with also tumor-promoting
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Figure 1. Stratiﬁcation of DLBCL patients according to subgroup. (A) Subdivision of DLBCL patients into subgroups DLBCLa and DLBCLb
based on a 23 biomarker signature identiﬁed in our previous study.1 (B) Kaplan–Meier plot demonstrating OS of DLBCLa and DLBCLb, log-rank
P= 0.07 for OS. (C) Kaplan–Meier plot demonstrating FFS of DLBCLa and DLBCLb, log-rank P= 0.05 for FFS.
Table 1. Results of the Cox regression analysis
Factor Variables HR 95% CI P-value
OS aaIPI 2.2 1.0–4.7 0.05
aaIPI 2.0 0.9–4.4 0.08
TNF-a 1.5 0.2–9.8 0.70
IL-10 3.0 0.6–15.5 0.20
aaIPI 2.1 0.9–4.5 0.07
TNF-a 3.4 0.9–13.1 0.08
aaIPI 2.0 0.9–4.5 0.07
IL-10 3.7 1.1–12.3 0.03
aaIPI 2.2 1.0–4.8 0.05
DLBCLa/b 1.9 0.9–3.9 0.11
FFS aaIPI 2.0 1.0–4.4 0.06
aaIPI 2.0 0.9–4.1 0.10
TNF-a 1.5 0.2–9.7 0.67
IL-10 2.8 0.6–14.6 0.21
aaIPI 2.0 0.9–4.2 0.08
TNF-a 3.3 0.9–12.7 0.08
aaIPI 1.9 0.9–4.2 0.09
IL-10 3.6 1.1–11.7 0.03
aaIPI 2.1 1.0–4.6 0.05
DLBCLa/b 2.0 1.0–4.3 0.06
Abbreviations: CI, conﬁdence interval; DLBCL, diffuse large B-cell lym-
phoma; FFS, failure-free survival; HR, hazard ratio; IL, interleukin; OS, overall
survival; TNF-α, tumor necrosis factor-α.
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effects.13 In accordance with our results, overexpression of both
IL-10 and TNF-α has previously been correlated to poor prognosis
of DLBCL patients.14,15 Moreover, when combining the informa-
tion regarding DLBCL subgroup with the aaIPI in a Cox survival
model, the model was improved for both OS and FFS compared
with using the aaIPI alone (Table 1).
Taken together, in this study we have expanded our
immunoproﬁling efforts of DLBCL by examining the immunopro-
ﬁles of DLBCL patients before and during treatment. The results
revealed DLBCL-associated plasma protein proﬁles, with the
potential to reﬂect both alterations in the host immune response
and the molecular pathogenesis of the tumor cells. New candidate
markers for prediction of treatment response and prognosis were
identiﬁed, and provide a basis for future investigations. As this
study was mainly aimed for discovery, our ﬁndings must be
validated in independent patient cohorts, to further examine the
use of plasma protein proﬁling as a novel possibility for
prognostication and prediction of treatment response in DLBCL.
Moreover, ongoing and future efforts to select further antibodies
with high speciﬁcity and stable on-chip function will allow us to
target a wider range of proteins, and enable an even more highly
resolved view of the complex plasma proteome in DLBCL.
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